Nanobiohybrids and bacterial carriers: a novel pathway to targeted cancer therapy

IF 2.5 4区 材料科学 Q3 MATERIALS SCIENCE, MULTIDISCIPLINARY Nano Futures Pub Date : 2024-09-15 DOI:10.1088/2399-1984/ad7802
Diyar Salahuddin Ali, Hazha Omar Othman, Sarhang Hayyas Mohammed, Rebwar Omar Hassan, Zahraa Sarkawt Faethullah, Roza Ibrahim Kareem and Slim Smaoui
{"title":"Nanobiohybrids and bacterial carriers: a novel pathway to targeted cancer therapy","authors":"Diyar Salahuddin Ali, Hazha Omar Othman, Sarhang Hayyas Mohammed, Rebwar Omar Hassan, Zahraa Sarkawt Faethullah, Roza Ibrahim Kareem and Slim Smaoui","doi":"10.1088/2399-1984/ad7802","DOIUrl":null,"url":null,"abstract":"The new strategies in this regard of nanotechnology and biotechnology guarantee new, efficient modalities for cancer therapy. In this study, we explore nanobiohybrids, the bacterium-targeted cancer treatment approach that presents a new category of therapeutic carriers for treating cancer. We specifically focus on bacteriomimetics, where bacteria are used as natural carriers for therapeutic agents. These bacteria possess the ability of pathotropism in localizing themselves around tumor tissues, even hypoxic areas that are generally refractory to standard therapies. By engineering the surface of these bacteria, we enhance how they target tumor cells so that treatment is delivered specifically to the tumor microenvironment with no or minimal systemic side effects. Furthermore, these synthetic nanoparticles inculcated into these bacterial systems stabilize drugs and also provide a way for controlled release, which is important to maintain therapeutic effectiveness. Our results established that such nanobiohybrids are capable of efficient delivery of chemotherapeutic agents and of conducting a local real-time therapeutic response from the perspective of personalized cancer treatment. This research implies a huge development in targeted therapy against cancer, and further work has focused on optimizing these biohybrid systems for clinical applications.","PeriodicalId":54222,"journal":{"name":"Nano Futures","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nano Futures","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1088/2399-1984/ad7802","RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

The new strategies in this regard of nanotechnology and biotechnology guarantee new, efficient modalities for cancer therapy. In this study, we explore nanobiohybrids, the bacterium-targeted cancer treatment approach that presents a new category of therapeutic carriers for treating cancer. We specifically focus on bacteriomimetics, where bacteria are used as natural carriers for therapeutic agents. These bacteria possess the ability of pathotropism in localizing themselves around tumor tissues, even hypoxic areas that are generally refractory to standard therapies. By engineering the surface of these bacteria, we enhance how they target tumor cells so that treatment is delivered specifically to the tumor microenvironment with no or minimal systemic side effects. Furthermore, these synthetic nanoparticles inculcated into these bacterial systems stabilize drugs and also provide a way for controlled release, which is important to maintain therapeutic effectiveness. Our results established that such nanobiohybrids are capable of efficient delivery of chemotherapeutic agents and of conducting a local real-time therapeutic response from the perspective of personalized cancer treatment. This research implies a huge development in targeted therapy against cancer, and further work has focused on optimizing these biohybrid systems for clinical applications.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
纳米生物混合物和细菌载体:癌症靶向治疗的新途径
纳米技术和生物技术在这方面的新策略为癌症治疗提供了新的高效模式。在本研究中,我们探讨了纳米生物混合物,这是一种以细菌为靶标的癌症治疗方法,是治疗癌症的新型治疗载体。我们特别关注细菌仿生学,即利用细菌作为治疗剂的天然载体。这些细菌具有在肿瘤组织周围定位的路径定向能力,即使是通常对标准疗法无效的缺氧区域也不例外。通过对这些细菌的表面进行工程设计,我们可以增强它们靶向肿瘤细胞的能力,从而将治疗药物特异性地输送到肿瘤微环境中,而且不会产生或极少产生全身副作用。此外,这些灌输到细菌系统中的合成纳米粒子还能稳定药物,并提供一种控制释放的方法,这对保持治疗效果非常重要。我们的研究结果表明,从个性化癌症治疗的角度来看,这种纳米生物混合物能够高效地输送化疗药物,并产生局部实时治疗反应。这项研究意味着癌症靶向治疗的巨大发展,进一步的工作重点是优化这些生物杂交系统的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nano Futures
Nano Futures Chemistry-General Chemistry
CiteScore
4.30
自引率
0.00%
发文量
35
期刊介绍: Nano Futures mission is to reflect the diverse and multidisciplinary field of nanoscience and nanotechnology that now brings together researchers from across physics, chemistry, biomedicine, materials science, engineering and industry.
期刊最新文献
Nanobiohybrids and bacterial carriers: a novel pathway to targeted cancer therapy The use of orthogonal analytical approaches to profile lipid nanoparticle physicochemical attributes Navigating the frontiers of graphene quality control to enable product optimisation and market confidence Overlapping top gate electrodes based on low temperature atomic layer deposition for nanoscale ambipolar lateral junctions Turning CO2 into Sustainable Graphene: A Comprehensive Review of Recent Synthesis Techniques and Developments
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1